Use of clopidogrel and acetylsalicylic acid in complex treatment of cardiovascular diseases
Abstract
The article gives a brief overview of the recommendations for the prescription of acetylsalicylic acid and clopidogrel in patients with cardiovascular pathology, focusing on the possible benefits of using double antiplatelet therapy: acetylsalicylic acid and clopidogrel, as the most considerable PY-inhibitor.
About the Authors
M. V. Zhuravlyova
First Moscow State Medical University n.a. I.M. Sechenov; Scientific Centre for Expertise of Medical Application Products
Russian Federation
Russian Federation
A. B. Prokofyev
First Moscow State Medical University n.a. I.M. Sechenov; Scientific Centre for Expertise of Medical Application Products
Russian Federation
Russian Federation
S. Yu. Serebrova
First Moscow State Medical University n.a. I.M. Sechenov; Scientific Centre for Expertise of Medical Application Products
Russian Federation
Russian Federation
T. M. Ponomarenko
First Moscow State Medical University n.a. I.M. Sechenov
Russian Federation
Russian Federation
S. A. Belkov
First Moscow State Medical University n.a. I.M. Sechenov; Scientific Centre for Expertise of Medical Application Products
Russian Federation
Russian Federation
V. S. Krysanova
First Moscow State Medical University n.a. I.M. Sechenov
Russian Federation
Russian Federation
References
1. WHO GlobalInfoBase (http: www.infobase.who.int).
2. Национальные рекомендации: кардиоваскулярная профилактика. Всероссийское научное общество кардиологов, Москва, 2011.
3. Global status report on noncommunicable diseases, 2014.
4. Graham I, Atar D, Borch-Johnsen K, et al. European Atherosclerosis Society (EAS).Europe-an guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil. 2007 Sep; 14 Suppl 2: S 1-113.
5. ESC guidelines on the management of stable coronary artery disease The Task Force on the management of stable coronary artery disease of the European Society of Cardiology European Heart Journal (2013) 34, 2949-3003.
6. Roffi M et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) European Heart Journal, Volume 37, Issue 3, 14 January 2016, Pages 267-315.
7. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation European Heart Journal (2017) 00, 1-66.
8. Аверков ОВ, Аспирин и клопидогрел у больных инфарктом миокарда, подвергнутых реперфузионной терапии, Трудный пациент, ноябрь, 2006.
9. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336 (7637): 195-8.
10. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996 Nov 16.
11. Tan S et al. Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis. PLoS One. 2015 Aug 13; 10 (8).
12. Valgimigli M et al, 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS, European Heart Journal (2017) 0,1-48.
13. Mauri L et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med2014; 371: 2155-2166.
14. Hao PP, Zhang MX, et al. Clopidogrel 150 vs. 75 mg day (-1) in patients undergoing percutaneous coronary intervention: a meta-analysis. Journal of Thrombosis and Haemostasis, 4 Apr 2011 (9); 4: 627-637.
15. Zhao-Ke WU, Jing-Jing Wang JJ, Wang T, et al. Clopidogrel resistance response in patients with coronary artery disease and metabolic syndrome: the role of hyperglycemia and obesity. Journal of Geriatric Cardiology 2015; 12: 378-82.
16. Рекомендации по диагностике и лечению ИМ с подъемом ST. Кардиологический вестник, 2014; 4: 2-60,
17. Шишкова В. Н. Механизмы развития сердечно-сосудистых заболеваний при ожирении и инсулинорезистентности: фокус на атеротромботические осложнения, Российский кардиологический журнал № 9 (137), 2016.
Review
For citations:
Zhuravlyova M.V., Prokofyev A.B., Serebrova S.Yu., Ponomarenko T.M., Belkov S.A., Krysanova V.S. Use of clopidogrel and acetylsalicylic acid in complex treatment of cardiovascular diseases. Medical alphabet. 2017;2(31):5-9. (In Russ.)
Views:
285
Email this article 